$960 Million: A Preclinical TCE Just Goes Global!

On June 22, Antengene announced that it had entered into an exclusive licensing agreement with K2 Therapeutics (hereinafter referred to as "K2") for ATG-106. ATG-106 is a CDH6xCD3 bispecific T-cell engager (TCE) in preclinical development for the treatment of solid tumors.

Antengene also announced that it had entered into an option agreement with K2, granting the latter an option on an undisclosed preclinical bispecific TCE candidate for exclusive global development and commercialization rights.

Pursuant to the License Agreement and Option Agreement, K2 shall have the exclusive right to research, develop, manufacture, and commercialize the Licensed Products worldwide (excluding China).

Under the License Agreement, subject to the satisfaction of certain near-term conditions, Antengene is entitled to receive approximately USD 20 million in upfront and near-term consideration, including cash and minority equity interests in the licensee and its affiliates. Antengene is also eligible to receive up to USD 960.5 million in development, regulatory, and commercial milestone payments.

Pursuant to the Option Agreement, upon K2's exercise of the option, Antengene shall be entitled to receive an upfront payment and near-term consideration totaling approximately USD 20 million, including the option exercise fee, near-term payments, and the upfront payment, as well as a minority equity interest in the relevant asset-holding company. Antengene will also be eligible to receive up to USD 960.5 million in development, regulatory, and commercial milestone payments associated with the undisclosed TCE program.

The transferee, K2, was independently incubated by MPM BioImpact, a globally renowned biomedical investment institution. Positioned as a cross-regional platform for the translation of innovative assets, K2 is not restricted by molecule type or disease area. It specializes in identifying high-quality early-stage preclinical and clinical innovative pipelines in both China and the United States and advancing their global development.

MPM, the incubator, manages over $3.5 billion in assets and boasts more than 30 years of experience in pharmaceutical company incubation and M&A exits. Historically, its incubated companies have collectively launched approximately 60 FDA-approved drugs and completed over 120 IPOs and M&A exits. Recently, it finalized a $1 billion cash acquisition of one of its incubated oncology companies, demonstrating comprehensive capabilities across the entire value chain, from asset incubation and clinical development to M&A exits.

Therefore, by partnering with USD-denominated incubation platforms such as MPM, Antengene can retain its core domestic market while leveraging the partner's capital and clinical resources to advance overseas development. Additionally, holding equity allows Antengene to share in the upside from future mergers and acquisitions, a strategy that better aligns with the current development needs of innovative pharmaceutical companies seeking to balance domestic commercialization with global value creation.

The asset ATG-106 included in this transaction is a preclinical bispecific T-cell engager (TCE) developed by Antengene using its proprietary AnTenGager platform. It targets CDH6, addressing two high-incidence cancers: ovarian cancer and clear cell renal cell carcinoma.

Notably, CDH proteins are highly expressed during embryonic development but exhibit minimal expression in normal adult tissues. In contrast, they are highly enriched in ovarian cancer and 786-O renal cell carcinoma. Consequently, the risk of off-target effects in normal tissues is significantly lower compared to broad-spectrum solid tumor targets such as Claudin and EGFR, thereby conferring an inherent safety window advantage.

From a technical perspective, Antengene's independently developed second-generation TCE platform, AnTenGager, employs a "2+1" bivalent binding structure and steric hindrance shielding technology. This design enables targeting of low-expression antigens while reducing the risk of cytokine release syndrome (CRS), offering broad application prospects in the fields of autoimmune diseases, solid tumors, and hematologic malignancies.

Preclinical data presented at the 2026 AACR Annual Meeting corroborated the aforementioned advantages: compared with the traditional 1+1 CrossMab control molecule, ATG-106 demonstrated a 100- to 400-fold enhancement in cytotoxic activity against CDH6-positive tumor cells. In humanized PBMC mouse models of renal cell carcinoma, a dose of 0.3 mg/kg achieved complete tumor regression in all animals, while pro-inflammatory cytokines such as IL-6 and TNF-α remained at low levels in vivo, indicating controllable immunogenicity risk in vitro.

In addition to ATG-106, K2 has also secured an option for a second undisclosed TCE program, establishing a portfolio comprising a "core pipeline plus backup reserve."

For Antengene, this signifies that its overseas collaboration has evolved from a single-product licensing deal to the comprehensive value output of its entire TCE platform, demonstrating that the multi-target adaptability of its AnTenGager platform has gained recognition from international capital. Domestically, the company retains full development and commercialization rights for its entire TCE pipeline in Greater China, enabling the simultaneous advancement of local clinical trials for multiple candidates, including those targeting CDH6, CD19, GPRC5D, and LILRB4. This strategy achieves market segmentation between domestic and international spheres, unlocking bidirectional value creation.

T-cell engager technology has undergone more than a decade of industrial development. Early approved products primarily targeted CD19 and BCMA in hematologic malignancies, with their clinical efficacy thoroughly validated. However, significant technical barriers have long persisted in the field of solid tumors. The immunosuppressive tumor microenvironment, low expression of target antigens, and severe cytokine release syndrome (CRS) toxicity resulting from systemic T-cell activation have narrowed the therapeutic window of first-generation unmasked T-cell engagers (TCEs), preventing most candidate molecules from advancing to late-stage clinical trials.

New-generation TCEs generally achieve tumor-localized specific activation through molecular engineering, with technical approaches such as steric shielding, conditionally activatable peptides, and cleavable linkers becoming hotspots in R&D.

Astellas and Vir's PSMA×CD3 bispecific antibody adopts a dual-masking design, while Chinese companies such as Antengene and Mabwell are simultaneously advancing pipelines featuring masked "2+1" structures. This molecular engineering approach can significantly broaden the dosing window and enhance clinical efficacy in solid tumors, representing one of the core competitive dimensions in the current therapeutic landscape.

Furthermore, the therapeutic boundaries of TCEs continue to expand. Beyond traditional hematologic malignancies, autoimmune diseases and solid tumors have emerged as two major growth markets.

In the autoimmune disease field, TCEs are leveraged for their potent B-cell depletion capabilities to treat chronic conditions such as systemic lupus erythematosus and rheumatoid arthritis. In the solid tumor sector, pipelines targeting CLDN18.2, CDH6, DLL3, Nectin-4, and other antigens are advancing rapidly. By 2026, multiple companies' candidates will have entered Phase II clinical trials, marking the industry's gradual entry into a period of clinical data validation for TCEs in solid tumors.

Amidst the iterative advancement of TCE platform technologies and the progression of clinical pipelines, global licensing and acquisition deals involving TCEs have intensified over the past two years, with multinational pharmaceutical companies continuously increasing their investments in differentiated second-generation TCE assets.

In terms of overseas transactions, MSD acquired the riTAC platform company's pipeline for $680 million, while Astellas licensed in a masked TCE for prostate cancer for nearly $1.7 billion. The trend of Chinese assets going global is even more active: MSD paid an upfront fee of $700 million to acquire Tongrun's TCE, and Keymed's TCE ultimately achieved exit via Gilead's acquisition through the NewCo model.

Amid the current wave of overseas expansion, Antengene has leveraged its comprehensive pipeline matrix spanning autoimmune diseases and solid tumors to secure two major licensing deals (including an agreement with Belgian pharmaceutical company UCB in March this year, granting UCB R&D, manufacturing, and commercialization rights, with a total deal value of $1.18 billion), becoming one of the few platform-based enterprises in China to have successfully completed overseas licensing deals in two major therapeutic areas.

Evidently, buyer preferences are shifting toward masked structures with differentiated safety profiles. Pipelines featuring antigen-gated activation and low CRS preclinical data are more likely to secure substantial upfront and milestone payments. High-quality, tissue-restricted solid tumor targets such as CDH6 from Antengene, combined with masked molecule design, have become a key asset portfolio sought after by overseas venture capital firms and MNCs. This represents the core rationale behind K2's significant investment in ATG-106.

Overall, the dividends of the TCE space have not yet been fully realized. There remains significant market potential in clinical breakthroughs for solid tumors and the expansion of new applications in the autoimmune field. Innovative pharmaceutical companies in China that possess proprietary, differentiated molecular engineering platforms will continue to generate high-value licensing deals, leveraging robust preclinical data and diversified overseas collaboration frameworks. As a result, the global industry influence of Chinese-developed bispecific antibody technologies is steadily increasing.